Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
RESEARCH TOOLSreports
CRNX Analyst Ratings
Strong Buy
13 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRNX Stock 12 Month Forecast
Average Price Target
$77.00
▲(105.55% Upside)
| Highest Price Target$97.00 | Average Price Target$77.00 | Lowest Price Target$55.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Initiated
02/11/25
Leerink Partners
Reiterated
02/04/25
Wolfe Research
Initiated
02/03/25
Jefferies
Upgraded
01/21/25
Piper Sandler
Assigned
01/15/25
H.C. Wainwright
Reiterated
01/13/25
Oppenheimer
Reiterated
01/13/25
Morgan Stanley
Reiterated
01/10/25
J.P. Morgan
Reiterated
01/10/25
JMP Securities
Reiterated
01/10/25
Citi
$74
Buy
97.54%
Upside
Reiterated
01/10/25
Crinetics Pharmaceuticals: Promising Phase 2 Results and Strong Growth Potential Lead to Buy Rating
LifeSci Capital
$82
Buy
118.90%
Upside
Reiterated
01/10/25
Crinetics Pharmaceuticals Receives Buy Rating on Promising Phase 2 Trial Results and Strong Financial PositionThis morning, Crinecs Pharmaceuc als (Nasdaq: CRNX) reported top- line Phase 2 open-label data with its once-daily oral ACTH-receptor antagonist, atumelnant, in adults with congenital adrenal hyperplasia (CAH). Recall that prior to the December 2024 approval of Neurocrine’s (Nasdaq: NBIX) twice-daily CRF1-r antagonist, Crenessity (crinecerfont), there were no available treatments for CAH beyond high-dose glucocorc oids (GCs). In CAH, long-term exposure to supraphysiological levels GCs is associated with harmful consequences ranging from metabolic disease, loss of bone density, and psychological disturbances.
Unknown Analyst
Not Ranked
Evercore ISI
$57→$72
Buy
92.21%
Upside
Reiterated
12/20/24
JonesTrading
$71
Buy
89.54%
Upside
Reiterated
12/09/24
We assign 95% probability of success for paltusotine and we do not anticipate an Ad Comm. We expect strong initial uptake based on KOL feedback indicating patient preference for a daily oral over depot injections. Paltusotine label will likely include both frontline therapy and switching regimen, a differentiator from oral octreotide which is approved for maintenance only. Crinetics is also finalizing a Ph3 protocol for paltusotine in carcinoid syndrome, and approval in this indication would more than double the market opportunity.Reiterate BUY and $71 PT.
Robert W. Baird
$62
Buy
65.51%
Upside
Reiterated
11/12/24
Crinetics Pharmaceuticals: Promising Future with Innovative Drug Developments and Strong Financial Position
Best Analysts Covering Crinetics Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy CRNX and Sell After:
1 Month
xxx
Success Rate
8/12 ratings generated profit
Average Return
+12.70%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +12.70% per trade.
3 Months
xxx
Success Rate
11/12 ratings generated profit
Average Return
+25.84%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 91.67% of your transactions generating a profit, with an average return of +25.84% per trade.
1 Year
Success Rate
11/18 ratings generated profit
Average Return
+43.24%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +43.24% per trade.
2 Years
xxx
Success Rate
19/28 ratings generated profit
Average Return
+68.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 67.86% of your transactions generating a profit, with an average return of +68.12% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CRNX Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
8
5
4
12
12
Buy
7
10
15
15
8
Hold
0
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
15
19
28
22
Each month's total comprises the sum of three months' worth of ratings.
CRNX Financial Forecast
CRNX Stock Forecast FAQ
What is CRNX’s average 12-month price target, according to analysts?
Based on analyst ratings, Crinetics Pharmaceuticals’s 12-month average price target is $77.00.
What is CRNX’s upside potential, based on the analysts’ average price target?
Crinetics Pharmaceuticals has 105.55% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRNX a Buy, Sell or Hold?
Crinetics Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 1 hold ratings and 0 sell ratings.
What is Crinetics Pharmaceuticals’s price target?
The average price target for Crinetics Pharmaceuticals is $77.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $97.00 ,the lowest forecast is $55.00. The average price target represents 105.55% Increase from the current price of $37.46.
The highest analyst price target is $97.00 ,the lowest forecast is $55.00. The average price target represents 105.55% Increase from the current price of $37.46.
What do analysts say about Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of CRNX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.